2nd Annual Pharmaceutical Congress on Paragraph IV Disputes and Settlements

Paragraph IV litigation is reaching an all-time high with almost $85 billion in product sales that potentially could be affected by pending litigation and more than twenty-five drugs going off patent before 2012. Today’s pharmaceutical companies, both brand and generic, have much at stake in this costly, complex and constantly changing area of patent litigation. CBI’s 2nd Annual Pharmaceutical Congress on Paragraph IV Disputes brings both sides of the issue together for two days of presentations and panel discussions to discuss litigation strategies, statutory guidelines, current cases and their landmark decisions. This timely and valuable content is designed to provide you with the information you need to know today for better business decisions tomorrow.

The majority of pharmaceutical antitrust issues arise from exclusion payments between brand and generic companies during patent dispute settlements. In July, the House Energy and Commerce Committee passed an amendment to America's Affordable Health Choices Act of 2009 that would prohibit reverse payment settlements between generic and brand drug companies.

In September, Senator Kohl reviewed his plans to pursue an alternate amendment to the Preserve Access to Affordable Generics Act. This would make significant changes to the proposed legislation of America's Affordable Health Choices Act.

FACULTY

• Michael P. Bauer, J.D., Ph.D., Intellectual Property Counsel, Hospira, Inc.

• Saralisa Brau, Deputy Assistant Director, Health Care Division, Federal Trade Commission
• James Burling, Partner, Antitrust Department, WilmerHale
• Mark Buscher, President, Synthon IP
• Arthur M. Dresner, Of Counsel, Duane Morris LLP
• Gloria M. Fuentes, Ph.D., J.D., Legal Director, Schering-Plough Corporation
• Robert J. Gunther, Jr., Partner, WilmerHale
• Scott Hemphill, Associate Professor, Columbia Law School
• Kurt Karst, Attorney, Hyman Phelps & McNamara, P.C.; a primary author of the FDA Law Blog
• Chad Landmon, Partner, Axinn, Veltrop & Harkrider LLP
• Geoffrey Levitt, Vice President and Chief Regulatory Counsel, Wyeth
• Gerald Masoudi, Partner, Covington & Burling LLP; Former Chief Counsel of the FDA
• Bruce Pokras, Senior Corporate Counsel, Pfizer Inc
• Pamela Politis, Ph.D., Esq., Patent Attorney, Endo Pharmaceuticals
• Cedric C.Y. Tan, Partner, Townsend and Townsend and Crew LLP
• Shashank Upadhye, Vice President and Global Head of IP, Apotex, Inc.
• Anthony J. Viola, Partner, Edwards Angell Palmer & Dodge LLP